Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 8zilucoplan 7ravulizumab 6fludarabine 5efgartigimod alfa 5Cyclophosphamide 5telitacicept 3Prednisone 3inebilizumab 2Rituximab 2Pyridostigmine Bromide 2tofacitinib 1thymoglobulin 1talquetamab 1remibrutinib 1prednylidene 1iptacopan 1eculizumab 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Walk Test 1Therapeutics 1Tacrolimus 1Steroids 1Robotic Surgical Procedures 1Psychodrama 1Prednisolone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Oxaloacetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myasthenia Gravis × HBM9161 × 1 year × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡